HSBC Balanced Advantage Fund
The scheme seeks to generate long term capital growth and income through investments in equity and equity related securities and fixed income instruments.
Growthvine rating: 3/5 — ranked #17 of 35 in category.
Fund basics
| Category | Hybrid: Balanced Advantage |
|---|
| NAV | ₹44.50 (as of 2026-08-21) |
|---|
| AUM | ₹1,518 Cr |
|---|
| Expense ratio | 1.81% |
|---|
| Riskometer | High |
|---|
| Fund manager | Neelotpal Sahai |
|---|
| Exit load | For units in excess of 10% of the investment, 1% will be charged for redemption within 365 days |
|---|
Performance & risk
| Sharpe ratio | 0.41 |
|---|
| Standard deviation | 7.79% |
|---|
| Max drawdown | -8.94% |
|---|
| Alpha | 0 |
|---|
| Beta | 0 |
|---|
Over 5 years, captured 95.1% of NIFTY 50 Hybrid Composite Debt 50:50 Index's upside and 65.2% of its downside.
Market cap allocation
| Large cap | 68.5% |
|---|
| Mid cap | 17.8% |
|---|
| Small cap | 13.8% |
|---|
Concentration
| Top 5 holdings | 22.4% |
|---|
| Top 10 holdings | 34.2% |
|---|
| Total holdings | 57 |
|---|
Top holdings
- HDFC Bank Ltd. — 5.4%
- ICICI Bank Ltd. — 5.0%
- Reliance Industries Ltd — 4.7%
- Aurobindo Pharma Ltd. — 3.8%
- Kotak Mahindra Bank Ltd. — 3.5%
- NABARD — 3.3%
- 7.06% GOI - 10-Apr-2028 — 3.3%
- Net Asset — 2.8%
- 7.37% GOI 23OCT2028 — 2.7%
- Larsen & Toubro Limited — 2.6%
Top sectors
- Banking & Financial — 20.1%
- Retail — 8.6%
- Pharma & Biotech — 5.7%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 0.8% | Q3 | #19 of 35 |
| 2025 | 2.8% | Q4 (Bottom) | #29 of 34 |
| 2024 | 15.4% | Q1 (Top) | #6 of 30 |
| 2023 | 18.0% | Q3 | #14 of 26 |